Zhejiang CONBA Pharmaceutical Co.,Ltd.

600572

CNE000001H86

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
4.2 ^CNY	+1.20%		-5.83%	-16.83%

07-09	Zhejiang CONBA Pharmaceutical Gets Drug Registration for Mucolytic	MT
06-27	CONBA Pharma's Unit Gets Nod to Market Antidepressant Drug; Shares Down 3%	MT

Zhejiang CONBA Pharmaceutical Co.,Ltd. announced that it has received CNY 1.09 billion in funding

January 11, 2018

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) announced a private placement of 156,600,000 common shares for gross proceeds of CNY 1,090,000,000 on January 12, 2018.

Latest news about Zhejiang CONBA Pharmaceutical Co.,Ltd.

Zhejiang CONBA Pharmaceutical Gets Drug Registration for Mucolytic	07-09	MT
CONBA Pharma's Unit Gets Nod to Market Antidepressant Drug; Shares Down 3%	06-27	MT
CONBA Pharmaceutical Gets Nod to Market Tadalafil Tablets; Shares Down 3%	06-27	MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-19	CI
Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.	03-31	CI
Shanghai-Listed Firms Actively Repurchase Shares as Regulators Focus on Market Value	02-01	MT
Shanghai Dingjia Trading Co., Ltd. agreed to acquire 20% stake in Shanghai Kede Network Technology Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd. for CNY 26 million.	01-31	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.	01-22	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	01-21	CI
CONBA Pharma Gets Nod to Trial Cough Medicine	11-28	MT
CONBA Pharma Unit's Acetyl Cysteine Granules Chosen for China's Centralized Drug Procurement	11-08	MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to S&P Global BMI Index	23-09-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to FTSE All-World Index	23-09-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd.	23-07-06	CI
CONBA Pharma Gets Drug Registration for Risperidone Oral Solution	23-05-25	MT
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) intends to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million.	23-04-28	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Zhejiang CONBA Pharmaceutical to Sell 7.8% Stake in Pharma Firm	23-03-20	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. acquired remaining 7.6665% stake in Zhejiang CONBA Health Technology Co., Ltd from Gao Jing and Hu Xiaodan for CNY 21.9 million.	23-03-16	CI
Zhejiang Int'l Group Co.,Ltd. announced that it has received CNY 399.999996 million in funding from Zhejiang CONBA Pharmaceutical Co.,Ltd.	23-03-15	CI

Chart Zhejiang CONBA Pharmaceutical Co.,Ltd.

Duration

Period

Chart Zhejiang CONBA Pharmaceutical Co.,Ltd.

More charts

Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-08-23 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang CONBA Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.2 CNY

Average target price

7.27 CNY

Spread / Average Target

+73.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.	-16.83%	1.45B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.38%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.08%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals